CN109280644A - Anti-human igg monoclonal antibody, its hybridoma cell strain and application - Google Patents
Anti-human igg monoclonal antibody, its hybridoma cell strain and application Download PDFInfo
- Publication number
- CN109280644A CN109280644A CN201811201438.0A CN201811201438A CN109280644A CN 109280644 A CN109280644 A CN 109280644A CN 201811201438 A CN201811201438 A CN 201811201438A CN 109280644 A CN109280644 A CN 109280644A
- Authority
- CN
- China
- Prior art keywords
- kit
- antibody
- monoclonal antibody
- cell strain
- hybridoma cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/035—Herpes simplex virus I or II
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to hybridoma cell strain and its secreted monoclonal antibody, the antibody can be specifically bound with human IgG.The invention further relates to the kits for including the hybridoma cell strain or monoclonal antibody.Monoclonal antibody of the invention shows good performance in terms of antibody purity, repeatability, antibody titer and stability.
Description
Technical field
The present invention relates to a kind of monoclonal antibody, in particular to a kind of monoclonal antibody of anti-human igg secretes the Dan Ke
The application of the hybridoma of grand antibody and the monoclonal antibody.
Background technique
Herpes simplex virus (herpes simplex virus, HSV) is that one kind has coating, genome for double-stranded DNA
Virus is widely present in nature, can infect people and many animals, especially has stronger preferendum to human skin tissue,
It is the common causative of skin disease and venereal disease.There are two serotypes for herpes simplex virus, comprising: herpes simplex virus type 1
(herpes simplex virus-1, HSV-1), herpes simplex virus type 2 (herpes simplex virus-2, HSV-2).
Genital herpes caused by HSV-1 and HSV-2 have resulted in increasingly severe society and public health problem.
The detection common laboratory method of herpes simplex virus at present has direct immunofluorescence or histochemical staining, virus purification
Culture, the experiment of antigen latex agglutination, Serum Antibody Detection and round pcr.The above method is each advantageous and insufficient.Immunofluorescence
Dyeing or immunohistochemical staining are directly to detect intracellular HSV specific antigen, can be used as the property made a definite diagnosis experiment.But disease damage skin
The cast-off cells acquisition link of skin mucous membrane is relatively difficult, reduces sensitivity.Virus purification culture is that HSV infectious laboratory is most quick
The diagnostic method of sense can carry out parting to HSV virus isolated strain.But cell culture is time-consuming, bothersome, limits in clinical examination
Application.Antigen latex agglutination test is to be combined into compound using the monoclonal antibody and latex molecule particles of specificity, when
In the presence of having HSV antigen in serum, Ag-Ab-latex polymer just will form, macroscopic agglutination phenomenon occur.
This method advantage is not need specific apparatus, easy to operate quick, the screening suitable for high-volume sample.But sensibility is poor,
Recall rate only has 50%.Round pcr detection sensitivity is high, and the virus quantity of as low as 3 PFU can be detected, tentatively show and facing
Superiority in bed virus examination.But PCR method high sensitivity, operating technology require it is high, it is easy to pollute and cause false positive, also need
Talent's technical training, specific apparatus and import reagent are wanted, is still had any problem in universal and popularization practical at present.Detect HSV serology
Antibody is still the method for clinically most common judgement HSV infection, and HSV specific antibody mainly has two class of IgG and IgM at present.
HSV-IgG concentration is higher in serum, and accuracy in detection is higher.Therefore it develops through the preferable anti-human igg of systemic evaluation result
Diagnostic reagent field has very extensive application to monoclonal antibody in vitro.
However, it is a complicated process that screening, which is used to prepare the monoclonal antibody of external diagnosis reagent, first have to obtain
Then good antigen carries out the evaluation of system to prepare enough antibody to antibody, obtain the time with clinical correlation
Antibody is selected, is redeveloped into detection reagent.Wherein, antibody titer, cross reactivity, stability and clinical effectiveness etc. are important
Factor of evaluation, if antibody titer height is reflected with antigen reactive minimum titre under a certain concentration, titre more low liter is higher；
Antibody cross reaction can influence the specificity of the antibody；The stability of antibody will have a direct impact on the reliability of final result, and
The poor antibody of stability is higher to preservation condition, operating condition requirement, to reduce its practicability as diagnostic reagent
And the reliability of result, and inevitably cause the rising of cost；Clinical test is then used to illustrate that antibody is diagnosing corresponding disease
Actual effect when disease or virus infection.
Summary of the invention
The object of the present invention is to provide a kind of anti-human igg monoclonal antibody, the hybridoma cell strain for secreting the antibody, containing upper
State monoclonal antibody or hybridoma cell strain kit and they detection people infect 1 type herpes virus IgG in purposes.
It is evaluated by systematicness, the antibody has preferable performance in all respects, is used to prepare to be suitable as immune diagnostic reagent
External diagnosis reagent case.
For this purpose, present inventor has performed numerous studies, it is immunized mouse by human IgG, through limiting dilution after cell fusion
Method is cloned at least 4 times, and until reaching monoclonal, the novel of 1 plant of energy stably excreting antibody is screened from obtained numerous clones
Hybridoma cell strain (Hybridoma), this hybridoma cell strain are denoted as hybridoma cell strain 5A3, and will on August 23rd, 2018
It is preserved in China typical culture collection center, the Chinese Wuhan Wuhan University, and deposit number is CCTCC NO:
C2018172, so as to complete the present invention.
In the first aspect, the present invention provides a kind of hybridoma cell strain, it is preserved in China typical culture collection
Center, deposit number are CCTCC NO:C2018172.
In the second aspect, the present invention provides a kind of monoclonal antibody, the monoclonal antibody can be special with human IgG
Property combine.
In one embodiment, the monoclonal antibody is not in conjunction with human IgG, mouse IgG, rabbit igg or ox IgG people IgM.
In another embodiment, the middle titer of the monoclonal antibody is 5 × 104And add in long-term preservation, heat
There is more preferably stability and reliability under fast mal-condition.
In one preferred embodiment, the monoclonal antibody is by the anti-of hybridoma cell strain secretion of the invention
Body.
In the third aspect, the present invention provides a kind of kit, the kit includes hybridoma of the invention
Strain or monoclonal antibody.
In a specific embodiment, the kit is colloidal gold immunoassay kit, chemical luminescence reagent kit, radiation
Immune reagent kit, enzyme linked immunological kit or fluorescence immunoassay kit.
In one preferred embodiment, the kit is chemical luminescence reagent kit.
In another embodiment, the kit is micro-fluid chip.
In the fourth aspect, the use of hybridoma cell strain or monoclonal antibody of the invention in reagent preparation box is provided
On the way.
In one embodiment, the kit is the kit based on immune detection, it is preferred that the kit is
Colloidal gold immunoassay kit, chemical luminescence reagent kit, radioimmunoassay kitss, enzyme linked immunological kit or fluorescence immunoassay reagent
Box.
In one preferred embodiment, the kit is chemical luminescence reagent kit.
In another embodiment, the kit is micro-fluid chip, it is preferred that the micro-fluid chip is based on
Immune detection.
In one embodiment, the kit is for detecting human IgG.
In one preferred embodiment, the human IgG is herpes simplex types 1 virus IgG.
In addition, additionally providing hybridoma cell strain of the invention or monoclonal antibody of the invention in preparation for 1 type list
Purposes in the kit of pure herpesviral detection.
The beneficial effect of monoclonal antibody of the invention is, firstly, its antibody titer is more usually used than in in-vitro diagnosis
Commercially available human IgG antibody it is high, have more preferably immune effect；Secondly, antibody of the invention and human IgG, mouse IgG, rabbit igg, ox
IgG, people's IgM no cross reaction have good specific binding capacity；Again, have more excellent than commercially available human IgG antibody
Long-term and thermal stability, that is to say, that extend service life and the condition of storage and operating condition of relative loose can be received,
To which cost be greatly saved；Finally, clinical trial shows that monoclonal antibody of the invention can be used for preparing herpes simplex types 1 disease
The chemical luminescence reagent kit of malicious IgG antibody detection, detection sensitivity detect specificity up to 100% up to 100%.
That is, monoclonal antibody of the invention is more in antibody titer, cross reactivity, stability and detection effect etc.
A aspect has shown good performance, to can be used for in-vitro diagnosis and comprehensive through systematicness evaluation the present invention provides a kind of
Conjunction ability anti-human igg monoclonal antibody outstanding.
Detailed description of the invention
Fig. 1 shows the SDS-PAGE electrophoresis after purification of antibody human IgG-Ab5 of the invention；
Fig. 2 shows the bioactivity figures of antibody human IgG-Ab5 of the invention；
Fig. 3 shows the clinical correlation of reagent of the present invention and commercial reagent.
Specific embodiment
Below in conjunction with specific embodiment and embodiment, it is specifically described the present invention, advantages of the present invention and various effects
It thus will clearly present.It will be understood by those skilled in the art that these specific embodiments and embodiment are for illustrating
The present invention is not intended to limit the present invention.
Throughout the specification, unless otherwise specified, terms used herein are interpreted as usual in this field
Used meaning.Therefore, unless otherwise defined, all technical and scientific terms used herein has and skill belonging to the present invention
One of art personnel understands identical meaning.Contradiction if it exists, this specification are preferential.
Antibody
As it is used herein, term " antibody " refers to immunoglobulin molecules, including but not limited to chimeric antibody, source of people
Change antibody, human antibody, CDR grafted antibody and antibody construct, such as scFv (scFv) or antibody fusion protein；In addition,
Further relate to recombination ground or synthetically generation/synthesis antibody.
In a preferred embodiment, antibody refers to the hybridoma for being produced from that deposit number is CCTCC NO:C2018172
The antibody of cell strain.
" antibody fragment " generally includes the antigen binding domain of parental generation antibody, light chain and/or heavy chain variable region, one or more
At least part of (such as six) CDR retains at least certain binding specificity of parental generation antibody.Particularly, herein
Parental generation antibody refers to the antibody for being produced from the hybridoma cell strain that deposit number is CCTCC NO:C2018172.Antibody fragment
Example includes but is not limited to Fab, Fab', F (ab') 2 and Fv segment；Homodimer；Linear antibodies；But chain antibody molecule, for example,
sc-Fv；And the multi-specificity antibody formed by antibody fragment.In general, when based on mole come expression activity, segment retain to
The few 50% combination activity to C reactive protein.Preferably compared with parental generation antibody, segment retain at least 60%, 70%,
80%, 90%, the 95% or 100% combination activity to herpes simplex types 1 virus IgG.
Preferably, antibody fragment refers to antigen binding domain, light chain and the heavy chain variable region or six CDR of antibody.
" antibody derivatives " refer to that antigen includes the conserved amino acid substitutes (referred to as " conservative variant ") of antibody, its life
Object activity does not change substantially compared with parental generation antibody.
The present invention provides the monoclonal in form of antibody.
As used herein, term " monoclonal antibody " refers to the antibody for being obtained from the group for substantially notifying antibody,
That is, except it is possible can be in addition to a small amount of existing abiogenous mutation, it is identical for constituting the individual antibody of group.For list
Antigen site, monoclonal antibody are high specials.Monoclonal antibody is advantageous, because they can pass through hybridoma
Zhu, which cultivates, to be obtained, and substantially not by the pollution of other immunoglobulins.
Kit
Diversified forms can be used in detection kit of the invention, for example, test paper, the reagent containing reagent needed for various tests
Box, micro-fluid chip etc. can manufacture kit according to standard step well known by persons skilled in the art.
Kit of the invention may include as needed container, chip, operation instructions, buffer, immune auxiliaries and/or
For carrying out diagnosing/detecting required other materials, structure and/or reagent.
Using being illustrated for fluorescence immunoassay to kit of the invention in embodiment, but it should not be construed as this hair
Bright kit is only limitted to fluorescence immunoassay.
Kit of the invention includes the anti-of the hybridoma cell strain for being produced from deposit number as CCTCC NO:C2018172
Body can exist in such a way that this field is conventional, for example, being present in container with dissolution or dried forms, be coated on solid phase
On carrier (for example, film, plate, pearl, particle (such as magnetic particle)), it is present in the chamber of chip with dissolution or dried forms, but
The invention is not limited thereto.
Since objective factors, the kits such as transport and place to use generally require to be suitble to be showed in all kinds of complex environments
Field detecting, therefore, the stability of raw material be restrict kit results an important factor for one of.Shown in embodiment 10 as follows
, antibody anti-human's IgG monoclonal antibody (being denoted as human IgG-Ab5) of the invention as chemical luminescence reagent kit raw material extreme
Under the conditions of more conventional anti-human igg monoclonal antibody possess better stability, thus make kit result reliability enhance simultaneously
In a disguised form reduce costs.
Antibody of the invention can come to use preferably 5~10 μ g/ml, more preferably 6 μ with the concentration of 0.5~10 μ g/ml
g/ml。
It is used to carry out diagnosing/detecting required other materials in kit of the invention to include but is not limited to remove the present invention
Antibody outside other anti-human IgG antibodies, antigen and/or human IgG in conjunction with human IgG antibody.Above-mentioned other materials can be with
The mode of this field routine exists, for example, be present in container with dissolution or dried forms, be coated on solid phase carrier (for example,
Film, plate, pearl, particle (such as magnetic particle)), it is present in the chamber of chip with dissolution or dried forms, but the present invention is not limited to
This.
For carrying out diagnosing/detecting required other structures including but is not limited to be used to sample knot in kit of the invention
Structure, the result for carrying out contrast structure and/or for observing detection process or structure.
It is used to diagnose/detect other required reagents in kit of the invention to include but is not limited to detergent, show
Toner and/or terminator.
In one embodiment, the antibody in kit of the present invention detectably marks.Ability can be used
Any marker and labeling method known to field technique personnel.For example, the marker that can be used in the present invention includes enzyme, puts
Injectivity isotope, colloidal metal, fluorescent chemicals, chemiluminescence compound and bioluminescent compound, but the present invention is not limited to
This.
Common marker may include enzyme (such as horseradish peroxidase, beta galactosidase, alkaline phosphatase), radiation
Property isotope is (such as32P or125I) etc., biotin, digoxin, colloidal metal (such as colloidal gold), fluorescent dye (such as fluorescein, sieve
Red bright, texas Red etc.), chemiluminescence compound or bioluminescent compound (such as dioxetane, luminol or acridine
Deng).Any markers step well-known in the art can be used, such as enzyme or the covalent coupling of biotin group, iodate, phosphorus
Acidification, biotinylation etc..
In some embodiments, for diagnose/detect one of required other materials or it is a variety of can also be with
Detectably mark.
In one preferred embodiment, kit of the invention is the reagent for detecting herpes simplex types 1 virus
Box.
Purposes
Anti-human igg monoclonal antibody of the invention or hybridoma cell strain can be used for related to the specific reaction of human IgG
Any purpose.Preferably, antibody of the invention or hybridoma cell strain can be used for detecting herpes simplex types 1 virus.
Antibody or hybridoma cell strain of the invention can detect the biological sample from the mankind.
As used herein, " biological sample " refers to sperm, lymph, serum, blood plasma, urine, synovia or spinal fluid.?
In preferred embodiment, biological sample refers to serum or blood plasma.
The method of immunoassays can be used quantitatively or the presence of qualitative detection human IgG, the immunoassays generally include
Biological sample is incubated for together with other materials needed for antibody of the invention and/or detection or is successively contacted, and by a variety of
The antigen that technology detection well known in the art combines.
Detection method includes but is not limited to autoradiograph, fluorescence microscopy, enzymatic reaction directly or indirectly, puts
Injectivity isotope method or non radioactive isotope method etc..These methods especially include western blot, overlapping measures, RIA (is put
Penetrate immunoassays) and IRMA (immune radiating immunoassays), GIA (colloid gold immune measurement), EIA (enzyme immunoassay (EIA)), ELISA
(enzyme linked immunosorbent assay (ELISA)), FIA (fluorescence immunoassay) and CLIA (chemiluminescence immunoassay).
In one embodiment, antibody of the invention or hybridoma cell strain are suitable for detection human IgG, thus diagnosis
Whether body infects herpes simplex types 1 virus.
Embodiments of the present invention are described in detail below in conjunction with embodiment, actual conditions are not specified in embodiment
, it carries out according to conventional conditions or manufacturer's recommended conditions.Production firm is not specified in agents useful for same or instrument, for that can lead to
Cross commercially available conventional products.
1 mouse of embodiment is immunized
People's blood source IgG antigen (Sichuan mikey biology new material technology Co., Ltd, lot number 031524) is used into physiological saline
It is diluted to 2.0mg/ml, (100 μ g/ are only for mixing in equal volume with Freund's complete adjuvant (Sigma company, article No. SLBF-9338V)
BALB/c mouse), it is oil emulsion with the emulsification of 1ml syringe, until the oil emulsion instilled in water does not disperse that cream can be stopped
Change, by the lotion with the dosage four limbs armpit of 100 μ l/ only be subcutaneously applied to BALB/c mouse (Chengdu reaches large Experimental Animal Center, 4
Week old female, 3) enhance immune after immune 14 days for the first time, take human IgG and incomplete Freund's adjuvant (Sigma company, article No.
SLBM9367V) mixing (50 μ g/ BALB/c mouse) emulsifies afterwards in equal volume, and immunizing dose is 50 μ l/, later every other week
Enhancing is immune primary, and tail blood is adopted before being immunized every time, separates serum, measures potency with indirect elisa method.After 3 times immune, own
Mice serum potency is greater than 1:106, can be used to merge.First 3 days of fusion takes human IgG normal saline dilution to 2.0mg/ml,
Mix (100 μ g/ BALB/c mouse) tail vein supplementary immunization in equal volume with physiological saline again, dosage is 100 μ l/.
The preparation of 2 hybridoma cell line of embodiment
The preparation of 2-1 feeder cells
Make feeder cells with normal 12 week old BALB/c mouse peritoneal macrophage.1 day before fusion, BALB/c takes eye
Blood draw neck put to death, 0.1% bromogeramine impregnate 1 minute, be transferred to 75% alcohol impregnate 1 minute, in super-clean bench with sterilize cut tweezer
Skin of abdomen, exposure peritonaeum are started from rear abdomen.With cotton ball soaked in alcohol wiping peritonaeum disinfection.With syringe injection 2ml RPMI1640 training
Nutrient solution pays attention to avoiding penetrating intestinal tube to abdominal cavity.The right hand fixes syringe, is retained in syringe needle intraperitoneal, left hand holds cotton ball soaked in alcohol
The culture solution of injection is then sucked out in gently abdomen massage 1 minute.1000r/min is centrifuged 5-10 minutes, abandons supernatant.With being added
20% newborn bovine serum, 1% dual anti-RPMI1640 culture solution are resuspended, and adjustment cell concentration is 2-5 × 105A/ml is added 96
Orifice plate, 100 holes μ l/, 37 DEG C, 5%CO2 culture.
The preparation of 2-2 immune spleen cell
Immune serum potency reaches 1:10 in Example 16BALB/c mouse extract eyeball blood sampling, and separate serum work
Positive control serum when for antibody test.It is dislocated lethal mouse by neck simultaneously, 0.1% bromogeramine immersion 1 minute is transferred to
75% alcohol impregnates 1 minute, in super-clean bench, in raising left abdomen skin on sterile plate, it can be seen that spleen is changed and cut
Tweezer cuts off peritonaeum with sterile, takes out spleen and be placed in the plate for having filled 10ml RPMI1640 culture solution, gently wash, and
Surrounding connective tissue is peelled off in carefulness.Spleen is moved into another plate for filling 10ml RPMI1640 culture solution, elbow tweezers are used
Or the curved needle head on 1ml syringe gently squeezes spleen (can also squeeze spleen with plunger), enters splenocyte
RPMI1640 culture solution in plate.For several times with suction pipe piping and druming, single cell suspension is made.It is big in splenocyte suspension in order to remove
Agglomerate can be filtered with 200 mesh copper mesh.Splenocyte suspension is harvested, 1000r/min is centrifuged 5-10 minutes, with RPMI1640 culture solution
Then cell is resuspended in 10mlRPMI1640 culture solution and mixed, taken above-mentioned suspension, add platform phenol indigo plant dye liquor by centrifuge washing 1-2 times
Make spare after viable count.Usual every mouse 1 × 108-2.5×108A splenocyte.
The preparation of 2-3 myeloma cell
The mode that myeloma cell maintains before merging, is most important to hybridoma is successfully obtained.Target is to make
The time that cell is in logarithmic growth is as long as possible, certainly cannot be less than 1 week before fusion.The cell frozen wants 2 weeks after recovery
Time could be likely to restore for the myeloma cell grown at least 5 days in the state for being suitable for fusion.During the cultivation process
Myeloma cell in logarithmic growth maintains in the culture medium containing 10% calf serum, and method is cultivated with 12 dress 5ml
The culture bottle of base is inoculated with 10 times of myeloma cells being serially diluted.After 1 week to cell is quite close and do not grew one bottle again
Sub-bottle culture.The typical doubling time is 14-16 hours.Myeloma cell's suspension preparation method: 48-36 hours before fusion,
Myeloma cell is expanded culture (is generally about needed the cell of 2-3 bottles of 25cm2 culture bottle cultures by the fusion experiment of one piece of 96 orifice plate
It is prepared).On the fusion same day, cell is gently blown down from bottle wall with glass dropper, is collected in 50ml centrifuge tube.1000r/
Min is centrifuged 5-10 minutes, is discarded supernatant.30ml RPMI1640 culture solution is added, it is primary with method centrifuge washing.Then by cell
It is resuspended to 10ml RPMI1640 culture solution, is mixed.Myeloma cell's suspension is taken, after adding 0.4% tire phenol indigo plant to make viable count
It is spare.When cell count, cell suspension 0.1ml is taken to be added in 0.9ml, mixes, counted with blood counting chamber.Cell density (a/
Ml)=(4 big lattice total number of cells ÷ 4) × 104× extension rate.
The selectivity culture of 2-4 cell fusion and hybridoma cell strain
Splenocyte and myeloma cell are mixed in 50ml centrifuge tube in the ratio of 1:8.5, add RPMI1640 culture
Liquid is mixed well to 40ml.1000r/min is centrifuged 5-10 minutes, and supernatant is exhausted as far as possible.Bottom of fusion pipe is tapped on palm,
Keep sedimentation cell loosely uniform；It sets in 37 DEG C of water-baths and preheats.With 1ml suction pipe 1 minute or so (Best Times are 45 seconds) plus pre-
50%PEG (PH 7.4) 1ml of heat to 40 DEG C, side edged shake gently mixing.Add 20-30ml pre- in 90 seconds with glass dropper
The RPMI1640 culture solution of heat to 37 DEG C；20-37 DEG C stands 10 minutes.700r/min is centrifuged 5-10 minutes, abandons supernatant.It is resuspended in
In RPMI1640 culture solution containing 1%HAT and 20% newborn bovine serum, it is averagely distributed into 10 96 porocyte culture plates.37
DEG C, 5%CO2 culture, next day adds the RPMI1640 culture solution containing 1%HAT and 20% newborn bovine serum to pore volume
90%.It is swapped out 1/2 culture medium in hole after 5 days with HAT culture medium, 1/2 culture medium in the hole that swaps out again after 7 days.
The screening of 2-5 positive hybridoma cell strain
People's blood source IgG to 2ug/ml, every hole coating in 96 hole elisa Plates are diluted with 0.06M pH9.6 carbonate buffer solution
100 μ l, for cells and supernatant after detection fusion.It is placed in 2-8 DEG C of refrigerator overnight, discards liquid in hole within second day,
ELISA washing lotion board-washing three times, pats dry, with the PBS of the 0.01M pH7.2 containing 10% calf serum, the hole 150ul/, 37 DEG C of closings 2
Hour, it pats dry, Vacuum Package is stand-by.The 9th day after cell fusion, take 100 μ l of cell conditioned medium in above-mentioned 96 hole enzyme mark detection plate
In, the sheep anti mouse of 10000 times of diluted horseradish peroxidases labels is added after ELISA washing lotion board-washing five times by 37 DEG C of incubation 40min
IgG (production of Sichuan mikey biology new material technology Co., Ltd, lot number 111418) 100 holes μ L/, 37 DEG C of incubation 30min are same as above
After board-washing, every hole is added 100 μ L and contains 0.1% (M/V) o-phenylenediamine, 0.1% (V/V) hydrogen peroxide, pH5.0 citric acid phosphorus acid buffering
Liquid, 37 DEG C of incubation 10min, every hole are added 50 μ L 2M sulfuric acid solutions and terminate reaction, and multi-functional readout instrument detects 450nm absorption value.
Mice serum is diluted to 100 times as positive control when merging, and 1640 complete culture solution of RPMI is negative right as negative control
According to OD value < 0.2, positive control OD value > 1.8 is that detection system is effective, when value >=2 sample OD × negative control OD value, for sun
Property, otherwise it is feminine gender.
The cloning of 2-6 positive hybridoma cell strain
According to the method bed board feeder cells for preparing feeder cells in 2 2-1 of embodiment, it is outstanding to prepare positive hybridoma cell
Liquid is diluted to every milliliter of dilution for containing 1 cell with the HT culture medium containing 20% serum, screens positive Kong Tongtong embodiment 2
2-5 method is continuously cloned 4 times or more, until reaching 100% monoclonal.
2-7 positive hybridoma cell strain freezes
It will be cloned into the cell of 100% monoclonal and indirect method test positive in 2 2-6 of embodiment, is transferred to the continuation of 24 holes
Culture, after being transferred to cell bottle when cell covers with 80% and expanding culture, sub-bottle is passed on when cell covers with cell bottle 80%, passage
Cell when growing to logarithmic phase, with appropriate serum-free RPMI-1640 culture medium cell dispersion bottle inner cell, collect cell suspension
In conical centrifuge tube, cell suspension volume V is recorded, takes appropriate cell suspension to carry out cell count, obtains cell suspension density
(a/ml), remaining 1000rpm abandon supernatant after being centrifuged 5min, and the cell of precipitating is calculated according to cell density and centrifugation precursor
Appropriate frozen stock solution is added into cell precipitation and adjusts cell density to 2-4 × 10 for number6A/ml (it takes and carries out counting confirmation in right amount,
If cell number not in range, is centrifuged again according to cell count total amount, appropriate frozen stock solution is rejoined, cell is finally made
Concentration is in 2-4 × 106A/ml), it is then sub-packed in sterile cryopreservation tube, cells frozen storing liquid is resuspended in every cryopreservation tube packing
0.5ml.Cell fusion once obtains the hybridoma cell strain of 1 plant of energy stably excreting anti-human igg monoclonal antibody altogether, is denoted as hybridizing
Tumor cell strain 5A3 was deposited in China typical culture collection center on August 23rd, 2018, and deposit number is CCTCC NO:
C2018172。
The preparation of 3 monoclonal antibody of embodiment
The BALB/c mouse of 12-14 weeks health is selected, every mouse peritoneal injects 0.5mL atoleine (Tianjin Ke Miou), and 7
Every mouse peritoneal injection 2 × 10 after it6A hybridoma.It can produce ascites after inoculating cell 7-10 days, observe daily small
Mouse ascites fluid production, if abdomen obviously expands, when touching, skin has tension, and neck can be drawn to put to death mouse, use dropper
Ascites is sucked in test tube, a mouse can obtain 1-5mL ascites.The ascites centrifuging and taking supernatant of collection, takes sample to be put in -20 DEG C of ice
Case saves.
The purifying of 4 monoclonal antibody of embodiment
It is placed in 2-8 DEG C of refrigerator and is thawed overnight on the day before -20 DEG C or less cryopreserved human IgG-Ab5 ascites are mentioned.It second day, will
Ascites mixing, 2-8 DEG C, 12000rpm centrifugation 20 minutes, degreasing and precipitating, supernatant dilute 5- with Mab Loading Buffer
10 times, then with 0.22 μm of membrane filtration.By liquid loading 5mL-mabselectsure medium after above-mentioned filter, instrument is purified using AKTA,
Collection penetrates.It is steady to baseline with equilibrium liquid balance chromatographic column after completion of the sample, using elution destination protein, collect big
Chromatographic column is cleaned with 0.1M sodium hydroxide after the completion of the eluting peak of 100mAu, elution, then saves chromatographic column.To elution
Destination protein neutralized, 0.1mL neutralizer is added dropwise in every ml eluent.It mixes after neutralizing, albumen is placed in 5L dialyzate
Dialysis, every two hour change a not good liquor, change liquid 3 times.The destination protein 12000rpm to have dialysed is centrifuged 20 minutes, supernatant is
Final finished, and carry out electrophoresis (as described in Figure 1).
The purity detecting of 5 monoclonal antibody of embodiment
Electrophoresis glass plate is assembled, the SDS-PAGE glue of the separation gel of lower layer 12% and the concentration glue on upper layer 5% is prepared.Group
Gel electrophoresis slot is installed, suitable 1 × electrophoretic buffer is added.After measuring antibody concentration, a small amount of antibody 20mM PBS is taken
It is diluted to about 1mg/mL concentration, 5 × sample buffer of 10 μ l is added in the antibody after taking 40 μ l to dilute, and 10 points are boiled after mixing
Clock, then with 5000rpm centrifugation 10 minutes, it is spare.Supernatant 10ul loading is gone, is first demarcated with 70V electrophoresis to concentration glue and separation gel
At line (about 15 minutes), with 140V electrophoresis until bromophenol blue will run out of gel and stop electrophoresis.After the completion of electrophoresis, from electrophoresis glass
SDS-PAGE glue is stripped down on plate, is put into dyeing liquor, glass plate is cleaned, dries spare.Current Coomassie brilliant blue dye liquor
Dip dyeing SDS-PAGE glue 30 minutes, then with Coomassie brilliant blue destainer glue to be eluted to background colourless (can appropriate heat decoloring).With
Gel imager takes pictures to PAGE glue, is analyzed by software image grayscale, estimates antibody purity.
6 hybridoma cell strain culture supernatant bioactivity of embodiment
People's blood source IgG (limited public affairs of Sichuan mikey biology new material technology are diluted with 0.06M pH9.6 carbonate buffer solution
Department, lot number 031524) to μ g/ml, every hole is coated with 100 μ l in 96 hole elisa Plates.It is placed in refrigerator and stays overnight for 2-8 DEG C, second day
Liquid in hole is discarded, ELISA board-washing is machine-washed three times, patted dry, with the PBS, 150 μ l/ of the 0.01M pH7.2 containing 10% calf serum
Hole, 37 DEG C of closing 2h abandon liquid, pat dry, for detecting cells and supernatant, ascites and antibody titer.The inspection of cell conditioned medium potency
It surveys, is diluted step by step again from the 1st hole to the 12nd hole with the PBS buffer solution 2 of 0.01M pH7.2.Mice serum is diluted to when merging
100 times are made positive control, make negative control, negative control OD value < 0.2, positive control OD with 1640 complete culture solution of RPMI
Value > 2.5 is that detection system is effective, on the contrary for feminine gender for the positive when value >=2 OD × negative control OD value.Detected value is minimum
Dilution ratio corresponding to positive hole is cells and supernatant potency, this hybridoma cell strain culture supernatant potency is up to 1:
4096 or more.Culture supernatant potency is shown in Table 1.
1 hybridoma supernatant potency result of table
The detection of 7 titer of ascites of embodiment
ELISA detection method is the same as embodiment 6.Method particularly includes: the 1st hole is former times ascites, with the PBS of 0.01M pH7.2
Buffer dilutes step by step again from the 2nd hole to the 7th hole 10, dilutes step by step from the 8th hole to the 10th hole with 2 times.When 11st hole is to merge
Mice serum is diluted to 100 times and makees positive control, and negative control, negative control OD are made with RPMI1640 complete culture solution in the 12nd hole
Value < 0.2, positive control OD value > 1.8 are that detection system is effective, on the contrary for the positive when value >=2 OD × negative control OD value
For feminine gender.Dilution ratio corresponding to the minimum positive hole of detected value is titer of ascites, this hybridoma cell strain (is denoted as hybridoma
Cell strain 5A3) prepared by anti-human igg monoclonal antibody (being denoted as human IgG-Ab5), testing result is shown in Table 2, as seen from Table 2 abdomen
Water potency is up to 1:1.6 × 106。
2 titer of ascites testing result of table
The detection of 8 antibody titer of embodiment
The antibody after purification prepared in embodiment 4 is uniformly first diluted to 1mg/ with the PBS buffer solution of 0.01M pH7.2
Ml does 10 times to the 4th hole since the 1st hole and dilutes step by step, and the 5th hole is done 2 times to the 11st hole and diluted step by step.Antibody titer determines mark
It is quasi-: with log (dilution) for abscissa, to make curve by ordinate of OD value, curvilinear equation is y=min+ (max-min)/(1+
10^ ((logEC50-x) × Hillslope)), using sigmaplot software matched curve, take potency=10logEC50.As a result
Show that antibody titer secreted by this hybridoma cell strain (5A3) is greater than 5 × 104.In kind two kinds of business of control test
Change anti-human igg monoclonal antibody B and C, by fitting, middle titer is below 5 × 104, lower than hybridoma of the invention
The antibody of secretion.Table 3 and Fig. 2 list titration result.
The detection of 3 antibody titer of table
| Enzyme mark hole serial number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Positive control |
| Antibody extension rate | 10 | 100 | 1×103 | 1×104 | 2×104 | 4×104 | 8×104 | 16×104 | 32×104 | 64×104 | 128×104 | 3.1254 |
| Extension rate Log value | 1 | 2 | 3 | 4 | 4.301 | 4.6021 | 4.9031 | 5.2041 | 5.5051 | 5.8062 | 6.10721 | 3.0364 |
| Human IgG-Ab5 | 3.0058 | 2.6899 | 2.5993 | 2.383 | 2.3103 | 2.0085 | 1.628 | 1.2697 | 0.9856 | 0.7672 | 0.62766 | Negative control |
| Commercially available B | 1.7556 | 1.5325 | 1.3441 | 1.1943 | 0.9887 | 1.0077 | 0.5463 | 0.4141 | 0.3335 | 0.3165 | 0.23698 | 0.037281 |
| Commercially available C | 3.5828 | 3.1533 | 2.72 | 2.6099 | 2.4823 | 2.1493 | 1.6787 | 1.1787 | 0.8462 | 0.5699 | 0.4415 | 0.038583 |
The detection of 9 cross reactivity of embodiment
(1) HRP marks human IgG-Ab5
Solution is prepared:
A.2mg/ml HRP:1mgHRP is dissolved in 0.5ml purified water (ready-to-use)
B.60mM sodium metaperiodate: 80.2mg sodium metaperiodate is dissolved in 6.25ml purified water (ready-to-use)
C.160mM ethylene glycol: 8.93ul ethylene glycol is added in 1ml purified water (ready-to-use)
D.1mg/ml sodium borohydride: 1mg sodium borohydride is dissolved in 1ml purified water (ready-to-use)
E. saturated ammonium sulfate
F.0.05M carbonate buffer solution (pH9.6): sodium carbonate 1.59g/L, sodium bicarbonate 2.93g/L
0.5ml sodium metaperiodate is taken to be slowly added dropwise in 0.5ml HRP, side edged mixes, 2-8 degree avoid light place 30min,
Take 0.5ml ethylene glycol is slowly low above-mentioned solution is added, side edged mixes, and room temperature is protected from light 30min, and the HRP of activation slowly adds
Entering in 0.5mg antibody (label is than being 1:2), during which 0.05M CB dialysed overnight changes the liquid once, the antibody in dialysis band is taken out,
Volume is calculated, 0.2ml sodium borohydride (sodium borohydride reacts addition when starting to generate bubble with water), 2-8 is added in every milligram of antibody
Degree reacts 2h, and isometric saturated ammonium sulfate solution is added in above-mentioned solution, and 2-8 degree places 2h, and 10000rpm is centrifuged 10min,
It discards supernatant, precipitating 20mM PBS redissolves, and 20mM PBS dialysed overnight takes out the human IgG-Ab-HRP marked, according to body
Product calculates respective concentration, and isometric glycerol is added and saves.
(2) it is coated with human IgG, mouse IgG, rabbit igg, ox IgG and the every hole 100ul of people IgM (2.5ug/ml), 4 spend night.10mM
The closing of (7.4)+0.5% casein of Tris-HCl, every hole 150ul, 37 degree of 2h.Anti-human igg-Ab5 is marked according to the above method, will be marked
The enzyme labelled antibody remembered carries out 1000,2000,4000 times of dilutions respectively, is reacted respectively with five kinds of envelope antigens, and enzyme mark is anti-
Body dosage is 50ul, and 37 degree incubations 30min, board-washing, colour developing, testing result is shown in Table 4, and human IgG-Ab5 and five kinds resist as the result is shown
Former equal no cross reaction.
4 cross reaction of table detection
| Human IgG-Ab5-HRP thinner ratio | 1000 times | 2000 times | 4000 times |
| Human IgG | 0.763 | 0.526 | 0.325 |
| Mouse IgG | 0.061 | 0.059 | 0.048 |
| Rabbit igg | 0.134 | 0.103 | 0.112 |
| Ox IgG | 0.086 | 0.093 | 0.072 |
| People IgM | 0.035 | 0.051 | 0.045 |
The verifying of 10 stability of embodiment
Human IgG-Ab5 monoclonal antibody of the invention can be applied to indirect method and detect the simple herpes virus infection serum of 1 type
Human IgG-Ab5 antibody is marked after HRP by embodiment 9 and is diluted with certain proportion by antibody, and is handled in 37 degree of water-bath acceleration
6 days, the sample of two various concentration gradients is detected after accelerating 6 days.Table 5 the result shows that, after the water-bath 6 days of 37 degree of antibody detect two
Gradient sample, signal retention rate meet reagent Platform Requirements 90% or more.
The verifying of 5 stability of table
11 clinical diagnosis of embodiment
Human IgG-Ab5 monoclonal antibody of the invention can be applied to indirect method and detect the simple herpes virus infection serum of 1 type
Its antibody is applied in our company's chemical luminescence reagent kit and is used as enzyme labelled antibody by antibody, detects the knot of clinical sample
The result that fruit shows commercial reagent box detection clinical sample with our company has 95% or more correlation, and inspection is listed in table 6
It surveys as a result, compared its correlation in Fig. 3.
6 Sample of table
It should be understood that the present invention disclosed is not limited only to specific method, scheme and the substance of description, because these
It is alterable.It will also be understood that purpose of the terminology used here just for the sake of the specific embodiment scheme of description, rather than
It is intended to limit the scope of the invention, the scope of the present invention is limited solely by the attached claims.
Those skilled in the art, which will also be appreciated that or be able to confirm that, uses no more than routine experiment, institute herein
The many equivalents for the specific embodiment of the invention stated.These equivalents are also contained in the attached claims.
Claims (10)
1. a kind of hybridoma cell strain 5A3 is preserved in China typical culture collection center, deposit number is CCTCC NO:
C2018172。
2. a kind of monoclonal antibody, the monoclonal antibody is as secreted by hybridoma cell strain described in claim 1.
3. a kind of kit, the kit includes hybridoma cell strain described in claim 1 or list as claimed in claim 2
Clonal antibody.
4. kit according to claim 3, the kit be colloidal gold immunoassay kit, chemical luminescence reagent kit,
Radioimmunoassay kitss, enzyme linked immunological kit or fluorescence immunoassay kit or the kit are micro-fluid chips；It is preferred that
For chemical luminescence reagent kit.
5. hybridoma cell strain described in claim 1 or monoclonal antibody as claimed in claim 2 are in reagent preparation box
Purposes.
6. purposes according to claim 5, the kit is the kit based on immune detection.
7. purposes according to claim 6, the kit is colloidal gold immunoassay kit, chemical luminescence reagent kit, puts
Penetrating immune reagent kit, enzyme linked immunological kit or fluorescence immunoassay kit or the kit is micro-fluid chip；Preferably
Chemical luminescence reagent kit.
8. purposes according to claim 5, the kit is for detecting human IgG.
9. purposes according to claim 8, the human IgG is herpes simplex types 1 virus IgG.
10. hybridoma cell strain described in claim 1 or monoclonal antibody as claimed in claim 2 are used for 1 type list in preparation
Purposes in the kit of pure herpesviral detection.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811023717 | 2018-09-04 | ||
| CN2018110237172 | 2018-09-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109280644A true CN109280644A (en) | 2019-01-29 |
| CN109280644B CN109280644B (en) | 2023-02-17 |
Family
ID=65177010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811201438.0A Active CN109280644B (en) | 2018-09-04 | 2018-10-16 | Anti-human IgG monoclonal antibody, hybridoma cell strain and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109280644B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111007249A (en) * | 2019-11-27 | 2020-04-14 | 迪瑞医疗科技股份有限公司 | Herpes simplex virus antibody IgG chemiluminescence immunoassay kit and preparation method thereof |
| CN114276456A (en) * | 2021-12-27 | 2022-04-05 | 青岛硕景生物科技有限公司 | Hybridoma cell strain secreting mouse anti-human IgG monoclonal antibody, monoclonal antibody secreted by hybridoma cell strain and application of hybridoma cell strain |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0198086A1 (en) * | 1984-09-28 | 1986-10-22 | Teijin Limited | Mouse human hybridoma producing antivirus human antibody, process for its preparation, and antivirus human monoclonal antibody |
| CN101113459A (en) * | 2007-07-16 | 2008-01-30 | 东莞太力生物工程有限公司 | Recombination duplicating deficient virus, pharmaceutical composition containing the virus and uses thereof |
| WO2008014390A1 (en) * | 2006-07-28 | 2008-01-31 | Idexx Laboratories, Inc. | Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies |
| CN101430329A (en) * | 2008-09-24 | 2009-05-13 | 王贤理 | Immunoglobulin G detection reagent |
| WO2011048043A1 (en) * | 2009-10-19 | 2011-04-28 | F. Hoffmann-La Roche Ag | NON-CROSS-REACTIVE ANTI IgG ANTIBODIES |
| CN102353777A (en) * | 2011-07-05 | 2012-02-15 | 深圳市卫武光明生物制品有限公司 | Kit and method for testing human cytomegalovirus IgG antibody |
| CN104650236A (en) * | 2013-06-28 | 2015-05-27 | 英科隆生物技术（杭州）有限公司 | Heterogenous conjugate and application thereof to RV (rubella virus) assay |
| CN107635581A (en) * | 2015-02-13 | 2018-01-26 | 赛诺菲 | Stable liquid preparation for monoclonal antibody |
| CN108330106A (en) * | 2018-03-30 | 2018-07-27 | 四川迈克生物新材料技术有限公司 | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application |
| CN108588030A (en) * | 2018-03-30 | 2018-09-28 | 四川迈克生物新材料技术有限公司 | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application |
-
2018
- 2018-10-16 CN CN201811201438.0A patent/CN109280644B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0198086A1 (en) * | 1984-09-28 | 1986-10-22 | Teijin Limited | Mouse human hybridoma producing antivirus human antibody, process for its preparation, and antivirus human monoclonal antibody |
| WO2008014390A1 (en) * | 2006-07-28 | 2008-01-31 | Idexx Laboratories, Inc. | Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies |
| CN101113459A (en) * | 2007-07-16 | 2008-01-30 | 东莞太力生物工程有限公司 | Recombination duplicating deficient virus, pharmaceutical composition containing the virus and uses thereof |
| CN101430329A (en) * | 2008-09-24 | 2009-05-13 | 王贤理 | Immunoglobulin G detection reagent |
| WO2011048043A1 (en) * | 2009-10-19 | 2011-04-28 | F. Hoffmann-La Roche Ag | NON-CROSS-REACTIVE ANTI IgG ANTIBODIES |
| CN102656460A (en) * | 2009-10-19 | 2012-09-05 | 弗·哈夫曼-拉罗切有限公司 | Non-cross-reactive anti IgG antibodies |
| CN102353777A (en) * | 2011-07-05 | 2012-02-15 | 深圳市卫武光明生物制品有限公司 | Kit and method for testing human cytomegalovirus IgG antibody |
| CN104650236A (en) * | 2013-06-28 | 2015-05-27 | 英科隆生物技术（杭州）有限公司 | Heterogenous conjugate and application thereof to RV (rubella virus) assay |
| CN107635581A (en) * | 2015-02-13 | 2018-01-26 | 赛诺菲 | Stable liquid preparation for monoclonal antibody |
| CN108330106A (en) * | 2018-03-30 | 2018-07-27 | 四川迈克生物新材料技术有限公司 | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application |
| CN108588030A (en) * | 2018-03-30 | 2018-09-28 | 四川迈克生物新材料技术有限公司 | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application |
Non-Patent Citations (5)
| Title |
|---|
| HAOLIN LIU等: "A Rapid Method to Characterize Mouse IgG Antibodies and Isolate Native Antigen Bingding IgG B Cell Hybridoma", 《PLOSONE》 * |
| T MATHIESEN等: "Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separated IgG subclasses 1, 3 and 4 against herpes simplex virus", 《CLIN EXP IMMUNOL》 * |
| 李文等: "抗人IgG（Fc特异性）单克隆抗体的制备、鉴定及应用", 《空军总医院学报》 * |
| 段春光等: "抗人免疫球蛋白G多克隆荧光抗体的制备及在肾活检中的", 《医学研究生学报》 * |
| 王香菊等: "抗人免疫球蛋白IgG单克隆抗体制备及其特性鉴定", 《中国法医学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111007249A (en) * | 2019-11-27 | 2020-04-14 | 迪瑞医疗科技股份有限公司 | Herpes simplex virus antibody IgG chemiluminescence immunoassay kit and preparation method thereof |
| CN114276456A (en) * | 2021-12-27 | 2022-04-05 | 青岛硕景生物科技有限公司 | Hybridoma cell strain secreting mouse anti-human IgG monoclonal antibody, monoclonal antibody secreted by hybridoma cell strain and application of hybridoma cell strain |
| CN114276456B (en) * | 2021-12-27 | 2023-06-23 | 青岛硕景生物科技有限公司 | Hybridoma cell strain secreting mouse anti-human IgG monoclonal antibody, monoclonal antibody secreted by hybridoma cell strain and application of hybridoma cell strain |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109280644B (en) | 2023-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4707438A (en) | Immunoassay for breast cancer employing monoclonal antibodies | |
| CN108169492A (en) | It is a kind of to be used to detect colloidal gold immuno-chromatography test paper strip of bovine rota and its preparation method and application | |
| JPS63290965A (en) | Tumor specificity assay for ca125 ovarial cancer antigen | |
| CN109082413A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN109112114A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN104357401B (en) | Hybridoma, monoclonal antibody and the application of anti-II types dengue virus NS 1 monoclonal antibody can be secreted | |
| CN109187967B (en) | Duplex rapid detection card for detecting and distinguishing O-type and A-type foot-and-mouth disease viruses and preparation method thereof | |
| CN103048459A (en) | Immune detection reagent for detecting respiratory syncytial virus | |
| CN109112113A (en) | Monoclonal antibody, hybridoma cell strain, kit and its application of anti-human igg | |
| CN109734803A (en) | Anti-human MYO antibody and its application in detection kit | |
| CN109280644A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN108517315B (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN109266620A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN108330104B (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN108588031B (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN108588030B (en) | Anti-human IgM monoclonal antibody, hybridoma cell strain and application thereof | |
| CN108330105A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN105585633B (en) | The immune chromatography reagent kit of anti-human haemophilus influenzae P6 protein antibodies and the application antibody | |
| CN109055319B (en) | Anti- C reactive protein monoclonal antibody, its hybridoma cell strain and application | |
| CN111748528B (en) | Hybridoma cell strain secreting monoclonal antibody against fipronil and metabolite thereof and application of hybridoma cell strain | |
| CN114518447A (en) | Signal enhancement type colloidal gold immunochromatographic test strip for detecting bovine parvovirus and application thereof | |
| CN108330106A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN108384761A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN108531460A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN108517316A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 611731 1st floor, block B, building 1, No.8, Anhe 2nd Road, high tech Zone, Chengdu, Sichuan Applicant after: Sichuan ankerei New Material Technology Co.,Ltd. Address before: 611730 building 3, No.16, Baichuan Road, high tech Zone (West District), Chengdu City, Sichuan Province Applicant before: SICHUAN MACCURA BIOLOGICAL NEW MATERIAL TECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |